The APLAR 2020 preliminary program is now available! 

To view the preliminary program below, please select on the specific day tab that you wish and the individual program will be shown. 

The program is still under review and is subject to change. 

Pre-Congress program

Friday 23 October
1400-1700Pre-Congress workshop

CH 1
Biomechanics & Movement Workshop with BJC Health


Speakers:

Errol Lim
Managing Director of BJC Health

Dr Irwin Lim
Consultant Rheumatologist

Sarah Comensoli
Exercise Physiologist & Manager of Allied Health services

Dr Herman Lau
Rheumatologist

Robyn Yin
Head Exercise Physiologist

Belinda Price
Physiotherapist

Blanche Leung
Physiotherapist

Heidi Kim
Physiotherapist

Brought to you by

Featured program

Saturday 24 October
0945 – 1130CH1: Plenary session 1: Opening Ceremony and Management of rheumatic diseases during the COVID-19 pandemic

Chairpersons:
Tsutomu Takeuchi and Rohini Handa

Speakers
COVID-19 in rheumatology practice in Japan
Tsutomu Takeuchi, Keio University School of Medicine

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic
Ted Mikuls, University of Nebraska

RMD and COVID19: The EULAR perspective
Robert Landewe, University of Amsterdam
1130 – 1245CH2: Morning symposium 1

“Beyond remission” based on patients’ subjective experiences for improved RA control


Chairpersons:

Professor Masayoshi Harigai
Professor and Chairperson of Department of rheumatology/Tokyo Women’s Medical University

Speakers:

Associate Professor Yuko Kaneko
Associate Professor, Division of Rheumatology and Department of Internal Medicine/Keio University School of Medicine
CH3: Morning symposium 2

Solving the patient puzzle: A pragmatic approach to SpA management


Speakers:

Dr Mitsumasa Kishimoto
Associate Professor, Department of Nephrology and Rheumatology/Kyorin University School of Medicine

Dr Philip Robinson
Associate Professor/Brisbane Rheumatology

CH4: Morning symposium 3

New treatment paradigm in RA: Focusing on a novel JAK inhibitor


Chairpersons/Speakers:

Professor Tatsuya Atsumi
Professor of Medicine in the Faculty of Medicine/Hokkaido University

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Tsutomu Takeuchi
Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine
Brought to you by Brought to you by Brought to you by
1245 – 1315Break
1315 – 1445
CH1: Lunch symposium 1

Prospects for JAK inhibitors in the treatment of rheumatoid arthritis


Speakers:


Dr Kei Ikeda
Senior Lecturer, Department of Allergy and Clinical Immunology/Chiba University Hospital

Dr Akio Morinobu
Department of Rheumatology/Kyoto University Graduate School of Medicine


CH 2: Lunch symposium 2

Basic and Clinical of Rheumatology


Chairpersons:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health
Brought to you by
Brought to you by

1445 – 1500Break
1500 – 1640CH1: SpA – 1: New advances in Axial
Spondyloarthritis
CH2: SLE – 1: Progress and perspectives on SLE in the APLAR regionCH3: Imaging: Imaging in rheumatic diseases – where do we standCH4: Treating children with rheumatic diseases in Asia Pacific: The Great Divide
Chairpersons:
Mitsumasa Kishimoto, Katy Leung, Nazrul Islam
Chairpersons:
Sandra Navarro and Yoshiya Tanaka
Chairpersons:
Chi-Chen Chang and Ved Chaturvedi
Chairpersons:
Sumaira Farman and Surjit Singh
Outcome of Juvenile spondyloarthropathy in adulthood
Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences
Patient education as vital to improving outcomes
Laniyati Hamijoyo, University of Padjadjaran
Ultrasound and its clinical use in rheumatoid arthritis
Kei Ikeda, Chiba University Hospital
Asia-Pacific Pediatric Rheumatology: Where Do We Stand
Sumaira Farman, National Hospital & Medical Center; Al-Aleem Medical College; Fatima Jinnah Medical University
Improving Access to Care in Resource Challenged Settings: Lessons from the Paediatric Task Force Global MSK Health
Helen Foster, Newcastle University
Treat-to-Target in SpA, how far are we going?
James Wei, Chung Shan Medical University Hospital
Progress and Perspectives on SLE in the APLAR region
Evan Vista, St. Luke’s Medical Center and College of Medicine
Ultrasound in large vessel vasculitis
Kuo-Lung Lai, Taichung Veterans General Hospital
JIA: Geographic variability in treatment and long-term outcomes of JIA
Soamarat Vilaiyuk, Mahidol University
When and how to use, or not to use MRI in SpA”
Ashish Jacob Mathew, Christian Medical College
Interim report of the APLAR consensus statements on the management of SLE
Chi Chiu Mok, Tuen Mun Hospital
MRI in Rheumatoid Arthritis
Mami Tamai, Nagasaki University
Macrophage Activation Syndrome: Analysis of various Cytokines
Masaki Shimizu, Tokyo Medcial And Dental University
Novel assessment tool for bony damage in spondyloarthritis
Lai-shan Tam, The Chinese University of Hong Kong
Updates on the Asia Pacific Lupus Collaboration (APLC) cohort
Eric Morand
Ultrasound and its clinical use in spondyloarthropathy
Lee Ka Wing Gavin
Autoinflammatory disorders: Spectrum seen in Asia Pacific
Sulaiman Al-Mayouf, King Faisal Specialist Hospital & Research Center
Vasculitis: Childhood onset Takayasu arteritis: an update
Satish Kumar, Christian Medical College
Panel Q&APanel Q&APanel Q&APanel Q&A
1640 – 1740CH1: Abstract session: IgG4-RD, AOSD/sJIA, Kawasaki diseaseCH2: Abstract session: SLE and APL syndrome 1CH3: Abstract session: IIM, SSc, SjSCH4: Abstract session: COVID-19 and CTD
Chairperson:
TBA
Chairperson:
Sandra Navarro
Chairperson:
Yeong-Wook Song
Chairperson:
Rohini Handa
Increased Human Neutrophil Lipocalin and its Clinical Relevance in Adult-Onset Still’s Disease
Ji Li, Peking University International Hospital
Platelet Indices Could Be Simple, Reliable Predictors of Thrombotic Events in Patients with Antiphospholipid Syndrome
Yu Shi, Peking Union Medical College
Clinical and swallowing outcomes in patients with dermatomyositis and polymyositis with dysphagia using the Food Intake LEVEL Scale
Shin-ichiro Ohmura, Seirei Hamamatsu General Hospital
Rheumatic diseases on COVID-19 era
Selma Abdellaoui, Beni Messous Hospital
Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes
Eduardo Martín-Nares, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán
SLE Disease Activity Score (SLE-DAS) is a comparable disease activity measure to SLEDAI-2K
Masanori Kono, University of Tokyo Hospital
Immunomodulatory Therapy: a New Strategy for Dermatomyositis /Polymyositis
Shengxiao Zhang, The Second Hospital of Shanxi Medical University
Prevalence of emotional disorder and sleep quality in patients with systemic lupus erythematosus during COVID-19 epidemic: a cross-sectional study
Jing Zhu, Sichuan Provincial People’s Hospital
Abnormality of peripheral lymphocyte subsets in patients with Bechet’s disease and their restorations after receiving new immunomodulatory therapy
Shengxiao Zhang, The Second Hospital of Shanxi Medical University
Development of a genetic risk score for Filipino patients with systemic lupus erythematosus
Michael Tee, University of The Philippines
Characteristics And Outcomes Of Overlap Myositis: A Comparative Multigroup Study In Adults And Children with Idiopathic Inflammatory Myopathies (IIM)
Naveen R, Sanjay Gandhi Post Graduate Institute Of Medical Sciences
Factors associated with use of telemedicine for follow-up of lupus nepthritis in the COVID-19 outbreak
Ho So, The Chinese University of Hong Kong
Application Of Preliminary PRINTO Classification Criteria For SJIA In An Indian Cohort
Devang Pandya, Dev Children’s Hospital
The Association between Serum Leptin Levels, Body Mass Index, and Disease Activity in Women with Systemic Lupus Erythematosus
Nittayawadee Aeamsaard, Phramongkutklao Hospital and College of Medicine
Prognosis and Treatments of Patients with Myositis-associated Severe Interstitial Lung Disease: A Descriptive Study using National Inpatient Database in Japan
Hiroki Furuya, Chiba University Hospital
Spectrum Of Systemic Inflammatory Syndrome In Children During COVID 19 Pandemic In India
Devang Pandya, Dev Children’s Hospital
Long-term outcome of 21 cases of giant coronary aneurysm after Kawasaki disease – Our 40 years’ experience
Tomomi Sato, Shiga University of Medical Science
Joint Q&ANailfold Capillary Changes in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis
Tomohiro Sugimoto, Hiroshima University Hospital
Reactive arthritis after COVID-19 infection
Keisuke Ono, Kyorin University School of Medicine
Immunophenotypic analysis of peripheral blood mononuclear cells in IgG4-Related Disease
Aya Nishiwaki, The University of Tokyo
Is Rituximab an Adequate Glucocorticoid-Sparing Agent in Idiopathic Inflammatory Myopathies?
Bugra Han Egeli
A Healthy Dose of Skepticism: Eosinophilic Granulomatosis with Polyangiitis Initially Presenting as Possible COVID-19
Vincent Anthony Tang, University Of The Philippines – Philippine General Hospital
Joint Q&AJoint Q&AAssessing the Impact on Heath Seeking Behavior During COVID-19 Outbreak in a Group of Rheumatology Patients from Sri Lanka
Sunith Atukorale, Ministry of Health
Joint Q&A
1740 – 1840CH1: Evening symposium 1

Management of RA in 2020: is remission achievable and where do JAKs fit?


Speakers:

Professor Gerd-Rüdiger Burmester
Medicine Director of the department of Rheumatology

Associate Professor Peter Nash
Department of Medicine/University of Queensland, Brisbane, AUSTRALIA

CH2: Evening symposium 2

Treat-to-target in SLE: addressing short- and long-term treatment goals


Chariperson:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Ian Bruce
National Institute of Health Research (NIHR) Senior Investigator and Professor of Rheumatology/University of Manchester

Professor Nancy Agmon-Levin
Consultant/Tel Aviv and Chaim Sheba Medical Center

CH3: Evening symposium 3

ILD in Focus: Time to prioritize the lung in CTDs


Chairperson:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Professor Yannick Allanore
Professor of Rheumatology/University of Paris

Professor Marco Matucci-Cerinic
Professor of Rheumatology and Medicine at the Department of Experimental and Clinical Medicine/Careggi University Hospital of Florence
CH4: Evening symposium 4

Perspectives around the accumulated evidence for IL-6 in autoimmune disease


Chairpersons/Speakers:

Dr Kunihiro Yamaoka
Division of Rheumatology, Kitasato University Hospital, Japan

Dr Shinsuke Yasuda
Tokyo Medical and Dental University, Department of Rheumatology, Japan
Brought to you by Brought to you by Brought to you by Brought to you by
Sunday 25 October
1000 – 1130CH1: Plenary session 2: Past, present and future of rheumatology

Chairpersons:
Syed Atiqul Haq and Yoshiya Tanaka

Speakers:
Rheumatology: A Crystal Gaze? – a future perspective
Syed Atiqul Haq, BSM Medical University

Two decades of progress in rheumatology – what have we learnt?
Iain McInnes, University of Glasgow
1130 – 1245CH2: Morning symposium 5

Treatment of Rheumatoid Arthritis: Past and Future


Speakers:

Masaru Kato
Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University
CH3: Morning symposium 6

To continue, taper or discontinue biologics – Implications on RA treatment outcomes


Chairpersons:

Professor Yoshiya Tanaka
University of Occupational and Environmental Health, Kitakyushu, JAPAN

Speakers:

Associate Professor Peter Nash
Department of Medicine / University of Queensland, Brisbane, AUSTRALIA

Associate Professor Khoa Dinh Nguyen
Cho Ray Hospital, Ho Chi Minh City, VIETNAM

Professor Wen-Chan Tsai
Kaohsiung Medical University Hospital, Kaohsiung, TAIWAN
CH4: Morning symposium 7

Denosumab, anti-RANKL antibody, for the treatment of joint destruction in RA. − From DRIVE & DESIRABLE studies


Chairpersons:

Professor Tatsuya Atsumi
Professor of Medicine in the Faculty of Medicine / Hokkaido University

Speakers:

Professor Tsutomu Takeuchi
Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine
Brought to you by Brought to you by Brought to you by
1245 – 1315Break
1315 – 1445
CH1: Lunch symposium 3
New insights for clinical practice in Spondyloarthritis, SpA


Chairpersons:

Associate Professor Yuko Kaneko
Associate Professor, Division of Rheumatology and Department of Internal Medicine/Keio University School of Medicine

Professor Naoto Tamura
Professor and Chairman, Department of Internal Medicine and Rheumatology/Juntendo University School of Medicine

Speakers:

Dr Kei Ikeda
Senior Lecturer, Department of Allergy and Clinical Immunology/Chiba University Hospital

Dr Kenta Misaki
Chief Director, Department of Rheumatology/Kita-Harima Medical Center

Professor Yuho Kadono
Chief Administrator, Orthopedic Surgery/Saitama Medical University

Brought to you by
CH2: Lunch symposium 4

Innovative therapeutic alternatives for RA, PsA, AS and nr-axSpA: Individualising the treatment approach

Chairperson:


Dr Kunihiro Yamaoka
Division of Rheumatology, Kitasato University Hospital, Japan

Speakers:

Dr Kunihiro Yamaoka
Division of Rheumatology, Kitasato University Hospital, Japan

Professor Lars Erik Kristensen
Parker Institute / University Copenhagen

Professor Andrew Ostör
Cabrini Medical Centre / Emeritus Research

Brought to you by
1445 – 1500Break
1500 – 1640CH1: Merge of Basic and Clinical research in Vascultic disordersCH2: SLE – 2: SLE clinicalCH3: Genetics: recent progress in genetics of rheumatic diseasesCH4: SpA – 2: Updates in PsA
Chairpersons:
Debashish Danda, Xinping Tian and Masayoshi Harigai
Chairpersons:
Yoshiya Tanaka
Chairpersons:
Michael Tee and Zhanghou Li
Chairpersons:
Atimichi Morita and James Wei
Section 1: Update on vasculitis
Recent advances in AAV
Tony Sammel, Prince of Wales and Sydney Eye Hospitals
Management of systemic lupus erythematosus (SLE) during and beyond the COVID-19 pandemic
Sandra V. Navarra, University of Santo Tomas
GWAS, eQTL and epigenome of rheumatic diseases
Kazuhiko Yamamoto, RIKEN Center for Integrative Medical Sciences
Differential diagnosis of Psoriatic arthritis in daily practice
Mitsumasa Kishimoto, Kyorin University School of Medicine
Behcet’s disease – what is new?
Thurayya Arayssi, Weill Cornell Medicine
Genetic analysis of Takayasu arteritis
Ruchika Goel, Christian Medical College
Panel Q&AContinuing challenges in lupus nephritis
Daniel TM Chan, University of Hong Kong
Genetics of Kawasaki Disease: where are we in circa 2020
Surjit Singh, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education And Research, Chandigarh
Risk assessment and prevention of cardiovascular co-morbidities in psoriatic arthritis
Lai-Shan Tam, The Chinese University of Hong Kong
Section 2: APLAR Vascuilitis clinic – recent trends
Evaluation of large vessel vasculitis
Takahiko Sugihara, Tokyo Medical and Dental University
New trials with repurposed drugs in Takayasu arteritis
Xinping Tian, Peking Union Medical College Hospital
GCA and PMR in Australia: evolving treatment paradigms and clinical research
David Liew, Austin Health
Special issues on pregnancy and lactation
Aisha Lateef, Woodlands Health Campus
Genetic risk score
Sarah Reid
Biomarker for PsA – myth or reality
Katy Leung, Singapore General Hospital, Duke-nus Medical School
Current key areas in futuristic ‘state of the art’ vasculitis research
Masayoshi Harigai, Tokyo Women’s Medical University
Treatment update of PsA
Peter Nash, Griffith University
Panel Q&A
SECTION 3: Beginners research on vasculitic diseases
Panel discussion by young researchers

Carotid Doppler in Takayasu Arteritis
Kyaw Thura Zaw

GCA research in Adelaide
Jem Ninan

Suggestions on research in resource limited set up
Debashish Danda
Panel Q&APanel Q&APanel Q&A
1640 – 1740CH1: Abstract session: IIM, SSc, SjSCH2: Abstract session: SLE and APL syndrome 2CH3: Abstract session: OA and Crystal induced arthritisCH4: Abstract session: SpA, AS-1
Chairperson:
Layla Kazkaz
Chairperson:
Yoshiya Tanaka
Chairperson:
TBA
Chairperson:
Mitsumasa Kishimoto
Clinical Responses to Low-dose Interleukin-2 in Idiopathic Inflammatory Myopathies
Miao Miao, Peking University People’s Hospital
Leukocyte immunoglobulin-like receptor A3 (LILRA3) promotes lupus-like disease severity
Yundi Tang, Peking University People’s Hospital
The numeral changes of peripheral lymphocyte subsets in 238 patients with GOUT and their correlation analysis with disease activity
Lijun Zhao, The Second Hospital of Shanxi Medical University
Efficacy and Safety of Brodalumab, Anti-IL-17 Receptor A Monoclonal Antibody, for Axial Spondyloarthritis, A 68-Week Result of Phase 3 Study
James Wei
Prediction of myocardial abnormalities in systemic sclerosis, assessed in cardiac magnetic resonance imaging, by using artificial neural networks models
Masaki Haraoka, St. Marianna University School of Medicine
Should ophthalmologic evaluation be done as a screening test for new onset lupus patients with no eye complaint?
Seyedeh Tahereh Faezi, Tehran University of Medical Sciences
Subtype Genome-Wide Meta-Analyses of Clinically-Defined Gout Revealed Multiple Subtype-Specific Gout Loci and Enrichment of Selection Pressure on ABCG2 and ALDH2
Yusuke Kawamura, National Defense Medical College
Improvements in Patient-Reported Outcomes in AS Patients Treated With Golimumab: Sub-Analysis of Asian Patients Enrolled in Phase III Clinical Trials
Wen-Chan Tsai, Kaohsiung Medical University
Clinical analysis of dermatomyositis / polymyositis / cancer-associated myositis and related research on peripheral blood CD4 + T lymphocyte subsets
Pan-di Zhang, The Second Hospital of Shanxi Medical University
Long-term Remission in Systemic Lupus Erythematosus
Alireza Khabbazi, Connective Tissue Diseases Research Center
Systematic Review and Meta-Analysis of the Prevalence of Neuropathic-Like Pain and Pain Sensitisation in People With Knee and Hip Osteoarthritis
Luigi Zolio, Alfred Health
Abnormality of peripheral lymphocyte subsets in patients with ankylosing spondylitis and restoration after receiving immunoregulatory combination therapies
Shengxiao Zhang, The Second Hospital of Shanxi Medical University
Diagnostic Accuracy of Salivary Free Light Chain and Immunoglobulin Assays in Primary Sjögren’s Syndrome
Pulukool Sandhya, St Stephens Hospital Delhi
Voclosporin Has Demonstrated Efficacy in Asian Patients With Lupus Nephritis
Tatsuya Atsumi, Hokkaido University
A Randomised Placebo-controlled Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-synovitis of Knee Osteoarthritis (CurKOA trial)
Benny Samuel Eathakkattu Antony, University of Tasmania
Comorbidity Profiles among patients with Axial Spondyloarthritis
Fariz Yahya
The Artificial Intelligence for the Prediction of Focal Score of Labial Salivary Gland Biopsy in the Diagnosis of Sjogren Syndrome
Noboru Kitamura, Nihon University School of Medicine
Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: a Distinct Disease Subset from Young-onset Lupus Nephritis
Kazuoto Hiramoto, Keio University School of Medicine
The Trajectory of Exercise Adherence Over Time and the Effect of Theory-lead Intervention for Knee Osteoarthritis in Elderly
Limin Wang, Peking University
Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from C-axSpAnd
Philip Robinson, University of Queensland
Effects of Nintedanib in Asian Patients with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD): Subgroup Analysis of the SENSCIS Trial
Masataka Kuwana, Nippon Medical School
Thrombotic risk assessment in patient with systemic lupus erythematosus: validation of the adjusted-Global Antiphospholipid Syndrome Score (aGAPSS) in Thai patients
Wanitcha Chanloung, Chiang Mai University
The Prevalence and Incidence of Symptom Knee Osteoarthritis in the Middle-aged and Elderly: a National Survey from China
Limin Wang, Peking University
Imbalance of Th17/Treg In Cardiovascular Diseases of Patients With Ankylosing Spondylitis
Tingting Ding, The Second Hospital of Shanxi Medical University
Joint Q&AJoint Q&APrevalence and Clinical Features of Early-onset Osteoarthritis in a Large Scale Cross-sectional Study
Jiajing Peng, Peking University People’s Hospital
Joint Q&A
Joint Q&A
1740 – 1840CH1: Evening symposium 5

Addressing Unmet Needs in RA and PsA: The Right Drug for the Right Patient


Chairpersons:

Professor Tsutomu Takeuchi
Professor of Rheumatology,
Department of Internal Medicine/Keio University School of Medicine

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine / School of Medicine,
University of Occupational and Environmental Health

Professor Filip Van den Bosch
Professor of Rheumatology and Head-of-Clinic,
Department of Rheumatology
/ University Hospital of Ghent University

Professor Tsutomu Takeuchi
Professor of Rheumatology,
Department of Internal Medicine/Keio University School of Medicine

CH2: Evening symposium 6

Evolution of interleukin-6 inhibiting therapies for rheumatoid arthritis


Chairpersons:

Dr Yutaka Kawahito M.D., Ph.D.
Head of the Department of Inflammation and Immunology/Kyoto Prefectural University of Medicine

Speakers:

Professor Motomu Hashimoto
Department of Advanced Medicine for Rheumatic Diseases, Kyoto University.
Brought to you by
Brought to you by

Text

Text

Text

Test
TEST
Translate »
Loading...